Understand the source comparison
Cerebrolysin Work for TBI Research: Study Type Comparison
Preclinical (Rodent CCI Models) Lesion volume, apoptotic cell count, neurobehavioral testing (Morris water maze, rotarod) 2.5–5.0 mL/kg daily × 7–14 days 30 min–6 hours Strong. 22–35% lesion reduction, improved motor recovery by day 7 Highly controlled, reprod
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Preclinical (Rodent CCI Models)
- Lesion volume, apoptotic cell count, neurobehavioral testing (Morris water maze, rotarod)
- 2.5–5.0 mL/kg daily × 7–14 days
- 30 min–6 hours
- Strong. 22–35% lesion reduction, improved motor recovery by day 7
- Highly controlled, reproducible; limited translational validity due to species differences in injury pathophysiology
- Phase II Clinical Trials
- Glasgow Coma Scale, Disability Rating Scale, adverse event frequency
- 30mL daily × 10 days
- 24–48 hours
- Moderate. Significant GCS improvement (p<0.05) but small sample sizes (n=60–120)
- Establishes safety and preliminary efficacy; underpowered for mortality or long-term functional outcomes
- Phase III RCTs
- Glasgow Outcome Scale at 90 days, mortality, cognitive testing (MMSE, Trail Making Test)
- 50mL daily × 21 days
- 12–72 hours
- Strong. Consistent GOS improvement (RR 1.32 for favourable outcome), no mortality benefit
- Best available human evidence; multi-centre design reduces bias but Eastern European trial dominance limits generalisability
- Systematic Reviews/Meta-Analyses
- Pooled effect sizes across trials for mortality, functional recovery, cognitive outcomes
- Variable (pooled from source trials)
- Variable
- Moderate-to-Strong. Demonstrates consistent benefit in survivors but highlights heterogeneity in dosing and endpoints
- Strongest evidence level for clinical decision-making; limited by quality and reporting standards of included trials